# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 4...
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting so...
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has be...
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of ...
Data Show Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccine ModalityLAWRENCEVILLE, N.J., Feb. 2...
– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month –
The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses...
Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-c...